Key Highlights
- Acrivon Therapeutics (NASDAQ:ACRV) lost USD 17.9 million, or USD 0.42 per share, in the quarter ended September 30, 2026, a slightly smaller per-share Deficit than the USD 0.47 of a year earlier.
- For nine months the loss shrank to USD 54.9 million from USD 58.9 million, with general and administrative outlays falling by USD 5.2 million, to USD 13.5 million.
- Management anticipates that USD 77.8 million of cash, equivalents and investments will sustain operations and Capital requirements into the fourth quarter of 2027.
- Disclosure highlights substantial doubt about Acrivon's footing as a going concern, while in November the company obtained the oral JAK1 inhibitor ACR-525 for consideration it deemed immaterial.
Lower Overhead Accounts for a Smaller Net Loss
The 10-Q for Acrivon Therapeutics (NASDAQ:ACRV), filed November 16, 2026, covers the third quarter that ended on September 30. This clinical-stage oncology developer applies its AP3 proteomics platform to pair therapies with patients and has no approved medicine or Revenue to date. Operating expenses for the quarter totalled USD 18.5 million, below the USD 19.7 million of the prior-year period. Research and Development climbed to USD 14.5 million, while G&A fell to USD 4.0 million, down from USD 6.0 million. Interest income was about half its prior level at USD 0.7 million, leaving the quarterly net loss at USD 17.9 million. Over nine months, employee-related costs, including stock-based pay, explain USD 4.2 million of the overhead decline.
Research Spending Centres on ACR-368 and Newly Licensed Assets
Nine-month R&D spending hit USD 43.6 million, of which USD 17.6 million backed the lead asset ACR-368 (prexasertib) and USD 4.7 million went to ACR-2316. ACR-368 works by blocking CHK1 and CHK2, and it sits in a Phase 2b registrational-intent study in endometrial cancer, where interim findings produced a 39% objective response rate in one arm. The serous endometrial arms are set for a prespecified interim analysis during the fourth quarter of 2026. In November the company also secured ACR-525, an oral JAK1 inhibitor for eosinophilic esophagitis, and a preclinical PKCθ program from Aqilion AB. According to the filing, no further milestone or Royalty commitments are outstanding.
Runway Into 2027 and the Going-Concern Flag
On September 30, 2026 Acrivon (NASDAQ:ACRV) had USD 77.8 million across cash, equivalents and investments, and management believes that balance will carry operations and capital spending into late 2027. The filing nevertheless states those funds will not last beyond 12 months from its date, which raises substantial doubt about the going-concern basis. Cash used in operations over nine months totalled USD 47.8 million, partly offset by USD 7.2 million of financing, mostly from an April 2026 at-the-market offering in which 4,054,954 shares were sold at USD 1.80, bringing in about USD 7.3 million before costs. The accumulated deficit stands at USD 329.8 million, and additional Equity issuance would dilute existing holders.
Where Things Stand
Acrivon Therapeutics (NASDAQ:ACRV) brought its nine-month loss down to USD 54.9 million, chiefly by trimming general and administrative costs USD 5.2 million, while research spending edged down only USD 1.7 million to USD 43.6 million. The cash total flatters the position: USD 77.8 million is projected to last into the fourth quarter of 2027, yet the filing itself flags going-concern risk. Nearer milestones include the fourth-quarter interim analysis for the serous endometrial arms of ACR-368 and whichever financing the company completes, which it has signalled it will need.





_11_19_2026_19_57_40_035532.jpg)
Please wait processing your request...